AFP and hepatocellular carcinoma: Despite these trends in early-stage diagnosis and AFP biomarker levels, first-line ORR in bridge to LT remains highly variable in the literature (23%–94%) [27,28,29,30,31,32], with up to 25% of candidates experiencing HCC progression while awaiting LT [33,34,35].